SPARCL1 and Alzheimer disease: Recently, mutations in SPARCL1 have been identified as accelerators of symptom onset in AD in addition to exerting influence on brain structure and function during the aging process, suggesting that Hevin may pose as a potential regulator of cognitive decline during aging (Seddighi et al. 2017).